--- title: "\"Big Banks\" JP Morgan: The strategic cooperation between INNOVENT BIO and Eli Lilly is a positive surprise, target price 111 yuan" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/275393309.md" description: "JP Morgan released a report stating that INNOVENT BIO has reached a strategic cooperation with Eli Lilly, focusing on novel biologics in the fields of oncology and immunology. They believe this cooperation is a positive surprise and marks an important milestone for INNOVENT BIO in advancing towards becoming a global biopharmaceutical company. The management of INNOVENT BIO reiterated its long-term vision, benefiting from a dual-engine growth strategy. JP Morgan reaffirmed INNOVENT BIO as one of its preferred targets, giving it an \"Overweight\" rating with a target price of 111 yuan" datetime: "2026-02-10T02:27:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275393309.md) - [en](https://longbridge.com/en/news/275393309.md) - [zh-HK](https://longbridge.com/zh-HK/news/275393309.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275393309.md) | [English](https://longbridge.com/en/news/275393309.md) # "Big Banks" JP Morgan: The strategic cooperation between INNOVENT BIO and Eli Lilly is a positive surprise, target price 111 yuan JP Morgan published a research report stating that INNOVENT BIO (01801.HK) has reached a strategic cooperation with Eli Lilly (LLY.US) to jointly develop new biological agents focused on oncology and immunology globally. The bank believes this cooperation is a positive surprise, marking another important milestone in INNOVENT BIO's journey towards becoming a global biopharmaceutical company, and highlighting the strength of its R&D platform. During a conference call, INNOVENT BIO's management reiterated its long-term vision, primarily benefiting from a dual-engine growth strategy in the areas of generic biopharmaceuticals and oncology drugs. The bank continues to be impressed by INNOVENT BIO's execution capabilities in its commercial and R&D product lines, as well as its strong business development capabilities. The bank reiterated that INNOVENT BIO is one of its preferred targets among the Chinese biotech companies it covers, maintaining an "Overweight" rating with a target price of 111 yuan ### 相關股票 - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [INNOVENT BIO (01801.HK)](https://longbridge.com/zh-HK/quote/01801.HK.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [Guotai CSI Hugangshen Innovative Drugs Industry ETF (517110.CN)](https://longbridge.com/zh-HK/quote/517110.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/zh-HK/quote/159570.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-HK/quote/513700.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) ## 相關資訊與研究 - [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/zh-HK/news/281644038.md) - [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-HK/news/281662341.md) - [Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead](https://longbridge.com/zh-HK/news/281538820.md) - [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/zh-HK/news/281035304.md) - [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-HK/news/281231901.md)